Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CEST

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
06/23 GLAXOSMITHKLINE PLC (ADR) (NYSE : GSK) Presents Positive Data From Phase III Shi..
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 GLAXOSMITHKLINE : Reports Findings in DNA Research (Ruthenium Promoted On-DNA Ri..
06/22 GLAXOSMITHKLINE : New Findings from GlaxoSmithKline plc in the Area of HIV/AIDS ..
06/22 RESEARCHERS FROM GLAXOSMITHKLINE PLC : A vaccine...
06/22 GLAXOSMITHKLINE : Study Results from GlaxoSmithKline plc in the Area of Influenz..
06/22 GLAXOSMITHKLINE : reports positive results with its shingles vaccine
06/21DJGLAXOSMITHKLINE : Shingles Treatment Meets Objective in Phase III Trial
06/16 GLAXOSMITHKLINE : GSK announces results from 10-year continuation study showing ..
06/16 Aspen loses Italy appeal over cancer drug prices
More news
Sector news : Pharmaceuticals - NEC
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/25 GLAXOSMITHKLINE : 3 Reasons You Should Be Concerned
06/25 WEEK IN REVIEW : Shenzhen's BGI Plans $250 Million China IPO To Support Genomics..
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 GILEAD : The Conundrum
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
Advertisement
Financials ( GBP)
Sales 2017 30 187 M
EBIT 2017 8 314 M
Net income 2017 4 337 M
Debt 2017 13 929 M
Yield 2017 4,68%
P/E ratio 2017 19,29
P/E ratio 2018 16,85
EV / Sales 2017 3,24x
EV / Sales 2018 3,13x
Capitalization 84 022 M
More Financials
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,9  GBP
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE9.38%106 833
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results